BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously

H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously

Leerink Partners initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $79.00

UBS initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $69.00

Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00

Scotiabank initiated coverage of Janux Therapeutics with a rating of Sector Perform and set a new price target of $47.00

BTIG Research initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $62.00

Cantor Fitzgerald initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $100.00

Wedbush initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $24.00

William Blair initiated coverage of Janux Therapeutics with a rating of Outperform

Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 $1.01 billion in cash, cash equivalents, and short-term investments at end of first quarter 2025 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported fina

Phase 1b expansion study initiated in taxane-naïve mCRPC patients Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Updates on JANX007 and JANX008 expected in the second half of 2025 Janux to host R&D Day in mid-2025 highlighting preclinical pipeline progression to the clinic Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC Enrollment ongoing for JANX007 and JANX008 Update on JANX007 and JANX008 data is anticipated in 2025 R&D Day is anticipated in 2025 to disclose new programs moving toward the clinic $1.03 billion in year-end cash, cash equivalents, and short-term investments Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth q

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.

Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 833,333 additional shares of common stock, at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded war

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gro

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock or, in lieu of common stock issued to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Janux expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offe

Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007 displayed: High PSA response rates: 100% achieved best PSA50 declines Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines Durable PSA response at ≥ 12 weeks: 75% maintained PSA50 declines; 50% maintained PSA90 declines Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8) Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2; Maximum tolerable dose has not yet been reached Janux to host virtual inv

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.

The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. "The appointment of Tommy to CSO is another important milestone for our company. Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our TRACTr and TRACIr platforms while supporting our clinical

Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened balance sheet with approximately $60 million offering Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah ("Zach") McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years of experience in clinical research, Dr. McIver joins Janux after serving as Amgen's Executive Medical Director, where he led cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. "Zach

-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022- -Management team and Board strengthened with key appointments- -Participating in upcoming virtual fireside chat- -$338.8 million in cash and cash equivalents and short-term investments at end of third quarter 2022- Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Ce

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Brenda Van Vreeswyk as Head of Human Resources (HR). Ms. Van Vreeswyk brings extensive HR leadership and operations expertise across the life sciences industry, including biopharma, diagnostics, and medical device companies, and most recently served as Director, HR for Neurocrine Biosciences. "We are excited to welcome Brenda to Janux as we continue making progress across our pipeline and

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Winston Kung to the Company's Board of Directors. Janux also announced that Stefan Heller, Ph.D., who has served on Janux's Board since 2018, has resigned. These changes are effective immediately. "On behalf of the Board and leadership of Janux, I would like to thank Stefan for providing his guidance and expertise over the last four years," said David Campbell, Ph.D., President and CEO of

–Company remains on-track to submit IND filings for two programs in 2022– –Company nominated its first TRACIr development candidate, a PD-L1 x CD28 costimulatory bispecific– –Management team strengthened with key appointment– –$375.0 million in year-end 2021 cash, cash equivalents and short-term investments– Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a busin

Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica